Revita.EPS, a proprietary peptide complex, is indicated to treat hypotrichosis (deficiency of hair) at the eyelashes by lengthening and thickening these specialized fibers. The deficiency to be corrected can be induced by genetics or exogenous factors such as chemotherapy.

In the $50 billion US cosmetics market, eye makeup represents a large and fast-growing segment. Prior to Revita.EPS, women had only mascara, prosthetics, and glaucoma drugs to enhance their eyelashes. Now Revita.EPS offers a safe, effective, affordable alternative.

Alternative to mascara. Containing waxes, pigments, resins, talc, and fibers, mascaras have been used historically to lengthen, thicken, and darken eyelashes. Mascara is quick and cheap, but it tends to clump, smudge, run down the face, and require reapplication constantly. Worse, it carries a high risk of bacterial and fungal contamination and infection of the eye. Unlike Revita.EPS, mascara products tend not to receive much biotechnical vigilance to improve their safety.

Alternative to prosthetics. False eyelashes, made of synthetic or donated human fibers, may look real at first glance, but soon appear as fake as they are. Strips of fibers are attached to delicate eyelids with adhesives based on methacrylate, a resin derived from methacrylic acid, which can result in contact dermatitis, as can the solvents used to remove it. Single extensions can be attached to individual eyelashes, which can appear more realistic but require more than an hour to apply and cost as much as $500.

Alternative to drugs. Bimatoprost (Latisse®) is a synthetic prostamide or prostaglandin analog approved by the US Food and Drug Administration for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Among its possible side effects are itching, changes in eye color, and the augmentation of eyelashes. Revita.EPS is not a glaucoma drug.

Alternative to transplantation. Surgical eyelash transplants have been performed, transferring hair follicles from the scalp onto the edges of the eyelids, but patients must trim and curl the implanted hairs, and possible complications include pain, bleeding, scars, numbness, ptosis (sagging), even blindness. Revita.EPS come with no reported side effects.

After chemotherapy. Powerful chemotherapeutic drugs attack not only cancer cells but also the rapidly growing cells that manufacture hair, causing hair loss all over the body, including eyelashes and eyebrows. Hair begins falling out in one to three weeks after starting chemo. It can happen quickly or gradually in clumps, resulting in a little thinning or complete baldness. It may take a few weeks after treatment for follicles to recover and begin growing again. New hair may be curly or unpigmented at first. Patients can try Revita.EPS to enhance eyelashes during this period.

Contraindications. Revita.EPS is contraindicated in patients with a hypersensitivity to peptides or any other ingredient in the product. There is a potential for hair growth to occur in areas where Revita.EPS comes in repeated contact with skin surfaces. The product should be used cautiously by patients with active intraocular inflammation.

For best results, apply Revita.EPS® twice daily, morning and evening. Start by ensuring that the face is clean and makeup is removed. Click the button to dispense the solution. Draw the applicator carefully across the skin of the upper eyelid as if applying eyeliner. Repeat for the lower eyelid. If solution gets into the eye, it is not expected to cause harm. The eye should not be rinsed.

After several weeks of use, you can switch to once-daily application and maintain the results already achieved.

PRECAUTIONS
For optimal hygiene and to limit any chance of eye infection, do not share your Revita.EPS pen with others. Take great care when applying to avoid eye injury. Proper application requires that you bring the tip close to the eye, and the product needs to be applied with a steady hand. Do not use this product if you cannot apply it safely.